AU2023371349A1 - Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8 - Google Patents

Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8 Download PDF

Info

Publication number
AU2023371349A1
AU2023371349A1 AU2023371349A AU2023371349A AU2023371349A1 AU 2023371349 A1 AU2023371349 A1 AU 2023371349A1 AU 2023371349 A AU2023371349 A AU 2023371349A AU 2023371349 A AU2023371349 A AU 2023371349A AU 2023371349 A1 AU2023371349 A1 AU 2023371349A1
Authority
AU
Australia
Prior art keywords
amino acid
seq
chain
cdr3 amino
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023371349A
Other languages
English (en)
Inventor
Duo AN
Songming PENG
Shan Zhong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neowise Biotechnology Co Ltd
Original Assignee
Neowise Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neowise Biotechnology Co Ltd filed Critical Neowise Biotechnology Co Ltd
Publication of AU2023371349A1 publication Critical patent/AU2023371349A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4244—Enzymes
    • A61K40/4253—GTPases, e.g. Ras or Rho
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
AU2023371349A 2022-11-04 2023-02-24 Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8 Pending AU2023371349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202211379445.6A CN115960204B (zh) 2022-11-04 2022-11-04 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN202211379445.6 2022-11-04
PCT/CN2023/078124 WO2024093056A1 (zh) 2022-11-04 2023-02-24 Kras_g12v突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞

Publications (1)

Publication Number Publication Date
AU2023371349A1 true AU2023371349A1 (en) 2025-05-22

Family

ID=87362539

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023371349A Pending AU2023371349A1 (en) 2022-11-04 2023-02-24 Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8

Country Status (5)

Country Link
EP (1) EP4613762A1 (https=)
JP (1) JP2025537239A (https=)
CN (2) CN115960204B (https=)
AU (1) AU2023371349A1 (https=)
WO (1) WO2024093056A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118852403A (zh) * 2023-04-26 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras突变的tcr分子和细胞及其应用
CN118852452A (zh) * 2023-04-28 2024-10-29 北京鼎成肽源生物技术有限公司 靶向kras g12突变的tcr分子和细胞及其应用
CN118909132A (zh) * 2023-05-06 2024-11-08 北京鼎成肽源生物技术有限公司 靶向kras g12v突变的tcr分子和细胞及其应用
WO2025056681A1 (en) * 2023-09-15 2025-03-20 Medigene Immunotherapies Gmbh T-CELL RECEPTOR AGAINST mKRAS7-16 G12V AND G12C
CN120157754A (zh) * 2023-12-14 2025-06-17 新景智源生物科技(苏州)有限公司 Kras_g12d突变抗原特异性tcr及其与cd8共表达重定向cd4 t细胞
CN120518771A (zh) * 2024-02-20 2025-08-22 上海信谱生物医药科技有限公司 一种识别kras突变的t细胞受体及其编码序列

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20200287A (es) * 2017-12-04 2020-11-11 Us Health Receptores de células t restringidos a antígeno leucocitario humano (hla) clase i contra sarcoma de rata (ras) mutado
CN112646024B (zh) * 2019-10-10 2023-03-24 香雪生命科学技术（广东）有限公司 一种识别kras突变的t细胞受体及其编码序列
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
CN112300269B (zh) * 2020-09-29 2022-12-09 中国科学院微生物研究所 Kras突变特异性t细胞受体筛选及抗肿瘤用途

Also Published As

Publication number Publication date
CN115960204A (zh) 2023-04-14
EP4613762A1 (en) 2025-09-10
WO2024093056A1 (zh) 2024-05-10
CN117430689A (zh) 2024-01-23
JP2025537239A (ja) 2025-11-14
CN115960204B (zh) 2023-08-25

Similar Documents

Publication Publication Date Title
AU2023371349A1 (en) Kras_g12v mutant antigen-specific tcr and redirected cd4 t cell co-expressing same and cd8
AU2023202035A1 (en) Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene
AU2024203874A1 (en) TCR and peptides
AU2024227695A1 (en) T cell receptors recognizing mutated p53
AU2024278090A1 (en) Inducible chimeric cytokine receptors
AU2023202184B2 (en) Methods and Compositions for Editing RNAs
AU2024227723A1 (en) Antigen discovery for T cell receptors isolated from patient tumors recognizing wild-type antigens and potent peptide mimotopes
AU2024205851A1 (en) XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
AU2024227645A1 (en) T cell receptor constructs and uses thereof
AU2025220738A1 (en) Compositions and methods of treating muscle atrophy and myotonic dystrophy
Ernst et al. Functional and biochemical association of Hck with the LIF/IL‐6 receptor signal transducing subunit gp130 in embryonic stem cells.
Austin et al. A role for the Wnt gene family in hematopoiesis: expansion of multilineage progenitor cells
AU2025204038A1 (en) Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
AU2025204695A1 (en) Anti-TCR antibody molecules and uses thereof
EP1698639B1 (en) Pluripotency determining factors and uses thereof
AU2024204188A1 (en) Multifunctional immune cell therapies
AU2024266817A1 (en) B cell maturation antigen binding proteins
Croy et al. Granulated metrial gland cells: a natural killer cell subset of the pregnant murine uterus
CN1934245B (zh) 多能干细胞的增殖方法
Rawlings et al. Long-term culture system for selective growth of human B-cell progenitors.
JP2008005845A (ja) 新規化合物
AU2025203767A1 (en) Manabodies And Methods Of Using
ES2361639T3 (es) Proteína específica de células pancreáticas beta de los islotes de langerhans y sus aplicaciones.
Strelchenko et al. Reprogramming of human somatic cells by embryonic stem cell cytoplast
Tong et al. In vivo analysis of undocked connexin43 gap junction hemichannels in ovarian granulosa cells